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Summary 
1 
Summary 
 
The aim of this study was to investigate the involvement of histamine H1 receptors in 
the amylin-leptin interaction using H1rKO mice. 
 
Compared with WT controls, 4-5 months old H1rKO mice had a significantly higher 
body weight, higher amount of fat mass and higher leptin levels; amylin and insulin 
levels were unchanged. No significant differences were detected in energy 
expenditure (EE), respiratory quotient or physical activity; however, H1rKO mice 
showed a tendency toward decreased EE. Food intake (FI) after a 6-hour fast was 
significantly higher. 
 
H1rKO mice were less responsive to amylin and leptin injections unless very high 
doses were used. Interestingly, the amylin-induced activation of neurons in the area 
postrema and the leptin-induced activation of hypothalamic nuclei were not affected, 
thus the reduced amylin and leptin action in H1rKO mice may not be due to the 
insensitivity at their primary brain sites. 
 
Finally, WT mice showed reduced FI after the combined amylin-leptin treatment, but 
H1rKO did not respond. 
 
With this study we showed that the lack of H1 receptors markedly reduced the 
anorectic effect of amylin and leptin. Since the primary responding brain areas were 
still responsive, as indicated by cFos and pSTAT3 signaling, the dysfunction of 
signaling seems to lie in the respective downstream pathways. 
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Zusammenfassung 
 
Ziel der Arbeit war es, den Einfluss von Histamin H1 Rezeptoren auf die Interaktion 
von Amylin und Leptin bei H1rKO Mäusen zu untersuchen. 
 
Verglichen mit WT Mäusen zeigten 4-5 Monate alte H1rKO Mäuse ein signifikant 
erhöhtes Körpergewicht, einen erhöhten Körperfettanteil sowie erhöhte Plasma-
Leptinwerte; Amylin und Insulin waren unverändert. Energieverbrauch, 
respiratorischer Quotient und körperliche Aktivität waren nicht signifikant verändert, 
trotz eines tendenziell erniedrigten Energieverbrauchs bei H1rKO Mäusen. Weiter 
zeigten diese Mäuse eine signifikant erhöhte Fasten-induzierte Futteraufnahme. 
 
Amylin und Leptin führten bei H1rKO Mäusen nur in sehr hohen Dosierungen zu 
einer Verzehrreduktion. Interessanterweise war die Amylin-induzierte Aktivierung 
von Neuronen in der Area postrema und die Leptin-induzierte Aktivierung gewisser 
hypothalamischer Kerngebiete nicht vermindert, so dass die reduzierte 
Verzehrsantwort bei den H1rKO Mäusen nicht auf einer Insensitivität der jeweils 
primär-rezeptiven Hirnareale zu beruhen scheint. Schliesslich zeigten nur die WT, 
nicht aber die H1rKO Mäuse eine reduzierte Futteraufnahme nach kombinierter 
Amylin/Leptin Gabe. 
 
H1 Rezeptoren sind offensichtlich an der Wirkung von Amylin und Leptin beteiligt. 
Da die entsprechenden primären Hirnareale sensitiv gegenüber Amylin bzw. Leptin 
bleiben, nehmen wir an, dass eine Signalstörung distal der primären Sensoren 
vorliegt. 
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1 Introduction 
 
1.1 Obesity epidemic 
 
Obesity is defined as an excessive amount of body fat in relation to lean mass of 
sufficient magnitude to produce adverse health consequences. Obesity results from an 
imbalance between energy intake and energy expenditure. Worldwide there are far 
more people dying from obesity and its complications, such as metabolic syndrome, 
insulin resistance and type 2 diabetes, fatty liver disease and cardiovascular disease, 
than from being underweight or malnourished (Flegal et al., 2007). Currently, over 
60% of American adults are overweight (BMI ≥ 25) or obese (BMI ≥ 30) and the 
obesity prevalence in adults and children keeps on growing dramatically (Zamboni et 
al., 2005). The World Health Organization illustrated the occurrence of overweight 
(937 million people) and obesity (396 million people) worldwide in 2005 and 
estimated that by 2030, the total number of overweight and obese people will reach 
1.35 billion and 573 million, respectively (Kelly et al., 2008). In Switzerland, the 
increase in overweight and obesity between 1992 and 2007 was also enormous; 
27’000 cases of type 2 diabetes, 63’000 cases of high blood pressure and 37’000 cases 
of dyslipidemia could have been avoided if people had not become overweight and 
obese over those 15 years (Davin et al., 2011). 
 
How to prevent and treat obesity is one of the most discussed topics in our society. 
Lifestyle change is the least intrusive way to counter obesity and eventually diabetes. 
However, additional treatments like surgical intervention or pharmacological therapy, 
e.g. hormonal treatment, are required when the disease worsens and lifestyle changes 
are no longer sufficient. Currently, surgical intervention is the only proven effective 
treatment of obesity that results in reduced mortality. Unfortunately, many body 
weight-lowering drugs have been developed but then again been withdrawn from the 
market due to unacceptable side effects. Since the central and peripheral mechanisms 
that play a role in the control of food intake and energy homeostasis are still not fully 
understood, and since the development of efficient and safe pharmacological 
treatments of obesity is rather limited, it is crucial to continue to investigate the 
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physiological processes that control feeding and energy balance.  
 
1.2 Physiological control of food intake 
 
The physiological control of food intake and body weight is maintained by a complex 
system in which many factors play a role. Energy balance is primarily regulated by 
neural and hormonal signals that are integrated in the brain (Seeley and Woods, 
2003). Of main interest are peripherally-produced hormones, some of which are 
considered physiological controllers of eating (Fig. 1.1).  
 
 
Figure 1.1: A diverse and complex network of circulating hormones and brain 
centers communicate to control food intake and body weight (Source Medscape: 
Expert Rev Clin Pharmacol © 2009 Expert Reviews Ltd) 
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Conceptually, there are two categories of peripheral signals that influence food intake. 
The first category includes short-term signals generated during meals. Such signals 
control two meal-related processes, including satiation (the termination of an ongoing 
meal) and satiety (the interval from the termination of one meal until hunger or the 
onset of the next meal). By stimulating the hindbrain directly or indirectly via sensory 
neuronal pathways, satiation signals inhibit food intake. Examples for this first 
category are cholecystokinin (CCK), amylin, peptide YY (PYY) and glucagon-like 
peptide-1 (GLP-1) secreted by the intestine and pancreas. 
 
Hormones secreted from the pancreatic islets and the adipose tissues comprise the 
second category of signals controlling food intake. The circulating levels of these 
adiposity signals, which include insulin (Lovett and Booth, 1970) and amylin (Morley 
and Flood, 1991) from the pancreas and leptin (Zhang et al., 1994) from adipocytes, 
are proportional to the amount of body fat and are thought to have effects on food 
intake and energy expenditure that control the long-term maintenance of energy 
homeostasis. 
 
An important anatomical structure for the control of food intake is the hypothalamus - 
hindbrain axis of the brain. Two hypothalamic regions especially relevant to the 
control of food intake are the arcuate nucleus of the hypothalamus (ARC) and the 
ventromedial hypothalamus (VMH). Additionally, regions of the hindbrain, like the 
area postrema (AP) and the nucleus of the solitary tract (NTS), are also important for 
the control of energy balance, in particular for meal-associated signals. Afferent fibers 
of the vagus nerve and visceral nerves via the spinal cord transmit information about 
the nutrient state to the hindbrain. Additionally, satiation and adiposity hormones 
circulating in the blood can either act on peripheral nerves (e.g. CCK), cross the blood 
brain barrier (BBB, e.g. insulin) or bind directly to areas of the brain that lack a 
complete BBB (e.g. amylin binding to AP). 
 
The ARC contains both insulin and leptin receptors (Plum et al., 2005); their 
activation influences the expression of various neuropeptides synthesized in the ARC 
that control feeding behavior. The major output of the ARC is to a pair of neuronal 
circuits with functionally opposite actions; one providing an anabolic tone and the 
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other providing a catabolic tone (Seeley and York, 2005). Catabolic neurons in the 
ARC synthesize pro-opiomelanocortin (POMC), which is processed into α-
melanocyte stimulating hormone (α-MSH) and other neuropeptides; α-MSH reduces 
food intake by binding to melanocortin 3 (MC3R) and melanocortin 4 (MC4R) 
receptors (Cone, 2005). The anabolic neuronal population in the ARC synthesizes 
neuropeptide Y (NPY) and agouti-related protein (AgRP) (Elmquist et al., 2005, 
Morton et al., 2006); they increase food intake by acting on Y receptors and by 
antagonizing MC3R and MC4R, respectively (Cone, 2005, Stanley et al., 2005). Both 
populations of ARC neurons project throughout the hypothalamus. Namely, the 
lateral hypothalamus (LHA) and the paraventricular nucleus (PVN) are richly 
supplied with NPY/AgRP- and POMC-expressing axons originating from insulin and 
leptin-sensitive ARC neurons (Elmquist et al., 1998, Elmquist et al., 1999). In fact, 
the PVN is thought to be the primary site of NPY action (Stanley and Leibowitz, 
1984, Billington et al., 1994).  
 
The VMH is another key hypothalamic nucleus controlling energy homeostasis. It has 
been shown that electrical stimulation of the VMH decreases food intake in food-
deprived animals (Anand and Dua, 1955, Oomura et al., 1967), while lesions of the 
VMH produce obesity and hyperphagia (Hetherington and Ranson, 1983, Bergen et 
al., 1998). The VMH also contains receptors for several neurotransmitters such as 
histamine, serotonin, GABA and dopamine, which are important for the control of 
feeding behavior, energy balance and glucose sensing (King, 2006). Furthermore, the 
VMH seems to be involved in the metabolic control of eating, e.g. by glucose. The 
glucostatic theory claims that the VMH is an important locus of glucose receptors that 
initiate satiety (Mayer, 1955, Marshall and Mayer, 1956). This theory is supported by 
the fact that a large part of VMH neurons are glucose responsive (Anand et al., 1964, 
Oomura, 1973, Song et al., 2001, Kang et al., 2004, Levin et al., 2004).  
 
The hindbrain plays an essential role in feeding behavior both by its role as major 
relay of afferent signals and by its motoneurons. In fact, all signals that control food 
intake must eventually engage the motor output circuits situated here (Grill, 2006). 
Regions of the hindbrain also integrate information from circulating hormones and 
metabolites, and they modulate vagally-mediated information from the gut and 
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periphery, before relaying this viscerosensory information to the forebrain. The NTS 
of the dorsal medulla represents the first central terminus for gastrointestinal and 
gustatory afferent fibers from the periphery (Norgren, 1978). Visceral information is 
then relayed to regions of the hypothalamus either directly or via the parabrachial 
nucleus (Herbert et al., 1990). Ascending catecholaminergic (CA) neurons of the 
NTS, many of which are believed to co-release NPY, target hypothalamic neurons 
(Sawchenko et al., 1985). The AP lies adjacent to the NTS. It is a circumventricular 
organ (CVO), and thus lacks a functional BBB (Gross, 1992), located at the floor of 
the 4th ventricle in the ventral medulla. The AP has reciprocal projections with the 
NTS and parabrachial nucleus and also receives afferent information from the 
glossopharyngeal nerve (van der Kooy and Koda, 1983, Shapiro and Miselis, 1985). 
As the AP receives gut and visceral information through these connections, and is 
sensitive to circulating signals indicative of the energy status in the internal milieu, it 
is in a unique position to integrate both circulating and peripheral sensory 
information, deeming this an important site for the control of autonomic function (Fry 
et al., 2007). 
 
1.3 Amylin  
 
Amylin is a satiation hormone, which is co-secreted with insulin by pancreatic β-cells 
in response to the intake of nutrients. During and shortly following food intake, 
circulating concentrations of both hormones increase significantly. The primary 
functions of amylin include the inhibition of gastric acid secretion, gastric emptying, 
pancreatic glucagon secretion, digestive enzyme secretion, and eating. Thus, 
following food intake, amylin acts to stabilize blood glucose levels and to promote 
satiation (Young and Denaro, 1998, Reda et al., 2002). Acute peripheral amylin 
administration reduces food intake dose-dependently, mainly by reducing meal size 
while having no effect on the following intermeal interval (Lutz et al., 1995). 
 
Amylin’s action depends on an activation of the central nervous system namely of the 
AP, which contains a high density of amylin receptors (Sexton et al., 1994). The role 
of amylin receptors expressed in other brain sites (Sexton et al., 1994, van Rossum et 
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al., 1994) is much less clear and their relevance for the control of eating has not been 
tested. 
 
The amylin receptor is a heterodimer, and all necessary components including the 
core calcitonin receptor (CT-R) and receptor-activity modifying proteins (RAMPs) 1 
or 3 (Christopoulos et al., 1999, Muff et al., 1999) are expressed in the AP. 
Furthermore it has been shown that AP lesions cause a loss of the anorectic effect of 
amylin (Lutz et al., 1998) and that local infusion of an amylin antagonist into the AP 
increases meal size (Mollet et al., 2004). Thus experimental data clearly indicate that 
the AP is the primary target site for amylin. 
 
Peripheral administration of amylin, at doses that are sufficient to reduce food intake, 
induces a strong cFos response in the AP and other brain areas. cFos is a nuclear 
protein used as an indirect marker for neuronal activity (Rowland et al., 1997, 
Edwards et al., 1998, Rowland and Richmond, 1999, Riediger et al., 2004) and that 
may be visualized by immunohistochemistry. Hence, by analyzing cFos expression 
after administration of amylin compared to controls, the relative amylin-induced 
neuronal activation can be quantified. Amylin induces cFos accumulation not only in 
the AP, but also in nuclei downstream of the AP, including the NTS, the external 
lateral parabrachial nucleus (LPBE), the central nucleus of the amygdala (CEA), and 
the lateral division of the bed nucleus of the stria terminalis (BSTL) (Rowland et al., 
1997, Riediger et al., 2004). Importantly, the amylin induced cFos expression in these 
projection sites is absent in AP lesioned rats. The LPBE, which projects to several 
hypothalamic nuclei including the ARC and VMH (Li et al., 1994), is also required 
for full expression of amylin-induced anorexia (Becskei et al., 2007). 
 
1.4 Leptin 
 
Leptin is the protein product of the obese gene (ob) and is primarily secreted by 
adipocytes of the white adipose tissue. Serum leptin concentrations are therefore 
directly proportional to the amount of body adipose tissue (Considine et al., 1996) at 
least under relatively weight stable condition (Gloy et al., 2010). Numerous studies 
indicate that the ARC is the primary site of leptin action (Baskin et al., 1999, Morton 
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et al., 2003). It has been shown using in situ hybridization that leptin receptor mRNA 
is highly expressed in the ARC, with lower levels also detectable in the VMH and the 
dorsomedial hypothalamus (DMH; Schwartz et al., 1996).  
 
Leptin is structurally related to cytokines (Zhang et al., 1997), and its receptor is 
member of the cytokine receptor superfamily (Tartaglia et al., 1995). Leptin binds to 
the long form of the leptin receptor (ObRb) and activates cytokine-like signal 
transduction cascades by stimulating the receptor-associated janus tyrosine kinase 2 
of the JAK-STAT (signal transducer and activator of transcription) pathway; this 
ultimately results in the phosphorylation of STAT3 (pSTAT3; Zhong et al., 1994, 
Ihle, 1995, Baumann et al., 1996, Ghilardi et al., 1996, Vaisse et al., 1996, Bjorbaek 
et al., 1997, White et al., 1997). The activated pSTAT3 is an indirect marker for 
functional leptin receptor activity. Following leptin administration, pSTAT3 signaling 
occurs in hypothalamic nuclei including the ARC and the VMH, but also in regions 
involved in reward mechanisms, including the ventral tegmental area (Fulton et al., 
2006, Hommel et al., 2006). Activation of STAT3 by leptin may be involved in 
changes in gene expression in leptin-responsive nuclei. For instance, stimulation of 
POMC gene expression in hypothalamic neurons seems to require the leptin-induced 
phosphorylation of STAT3 (Munzberg et al., 2003).  
 
Both centrally and peripherally administered leptin reduce food intake and increase 
energy expenditure, and consequently lower body weight when administered 
chronically (Halaas and Friedman, 1997, Hwa et al., 1997, Widdowson et al., 1997). 
This effect can be seen best in obese leptin-deficient mice (ob/ob) when leptin is 
administered because these mice are fully responsive to leptin. This results in reduced 
hyperphagia and obesity. In contrary, obese mice that are deficient in the leptin 
receptor (db/db) do not respond to leptin treatment (Halaas et al., 1995, Chen et al., 
1996). 
 
Interestingly, obesity in both humans and rodents, with the exception of ob/ob mice, 
results in high levels of circulating leptin, known as hyperleptinemia, but these 
elevated levels seem to be unable to reduce appetite or to increase energy expenditure. 
In other words, common obesity seems to be associated with a state of leptin 
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resistance, which is in principle comparable to hyperinsulinemia and insulin 
resistance occurring in many type 2 diabetes patients. The exact cause of the 
development of leptin resistance is not known, but multiple factors may contribute to 
the problem. One hypothesis suggests that elevated blood leptin levels may 
overstimulate leptin receptors. Overstimulation may eventually lead to an 
upregulation of negative feedback pathways which block further leptin signaling 
(Knight et al., 2010). This theory is supported by the fact that leptin also stimulates 
the expression of suppressor of cytokine signaling 3 (SOCS-3), a protein that directly 
inhibits leptin signaling (Enriori et al., 2007). Moreover, SOCS-3 is a negative 
regulator of pSTAT3 signaling. Leptin resistance develops most strongly in the ARC 
and is therefore associated with elevated SOCS-3 levels in the ARC (Munzberg et al., 
2004). Heterozygous SOCS-3 deficient mice are more sensitive to the weight-
reducing effects of leptin and are resistant to the development of obesity (Howard et 
al., 2004). Together, these data indicate that excessive activity of SOCS-3 may be a 
potential mechanism for leptin resistance, and that the inhibition of SOCS-3 
expression or function might therefore be a potential target for the development of 
drugs aimed at improving leptin sensitivity (Bjorbaek et al., 1998). 
 
Two additional theories purport to explain how rodents become leptin resistant. The 
first suggests that peripheral leptin becomes unable to reach its target in the brain due 
to saturation of the transporting system across the blood brain barrier. This may result 
in a reduced ratio of peripheral leptin to leptin levels in the cerebrospinal fluid (Caro 
et al., 1996, Banks and Farrell, 2003). The second theory states that leptin resistance 
is due to defects in CNS pathways that facilitate leptin’s effect. For instance, diet-
induced obesity (DIO) in rodents, which results in decreased leptin sensitivity, 
impairs the ability of leptin to activate hypothalamic signaling, such as the 
phosphorylation of STAT3 (El-Haschimi et al., 2000, Levin and Dunn-Meynell, 
2002). 
 
To investigate leptin resistance, DIO rodents are excellent models to clarify how 
leptin signaling becomes compromised when leptin resistance develops. C57BL/6J 
mice fed a high-fat diet (HFD) exhibit increased body adiposity along with other 
characteristics of human obesity, such as diabetes mellitus (>70% of mice on HFD) 
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(Burcelin et al., 2002). The development of obesity and leptin resistance in C57BL/6J 
mice kept on a HFD can be subdivided into two different stages of leptin resistance. 
In the early stage of obesity, mice are resistant to peripherally administered leptin. 
After long-term exposure to HFD for approximately 20 weeks, mice also become 
resistant to centrally applied leptin (El-Haschimi et al., 2000, Knight et al., 2010). In 
respect to the potential causes of leptin resistance, this time course suggests that a 
defect in BBB transport of leptin may have occurred earlier than defects in post-
receptor signaling. 
 
The occurrence of leptin resistance in both obese rodents and humans clearly 
demonstrates that leptin resistance is the main hurdle of leptin-based therapy. 
Investigations into the reversal of leptin resistance present some promising new 
avenues for obesity treatment. For instance, combined hormone therapies, such as 
amylin and leptin co-treatment, appear to enhance leptin function even in obese rats 
and humans. 
 
1.5 Amylin-leptin synergism 
 
Growing evidence demonstrates that amylin and leptin work synergistically, and not 
just additively (Trevaskis et al., 2008), to promote a greater decrease in body weight 
and food intake than either hormone alone (Roth et al., 2010). This effect has been 
observed in both lean and obese rats, as well as in clinical trials in humans.  
 
In lean rats, acute administration of central leptin increases the acute anorectic effect 
of peripheral amylin (Osto et al., 2007), while chronic peripheral administration of 
both hormones leads to a synergistic reduction in body weight and epididymal fat 
mass (Turek et al., 2010). Additionally, 14-day co-treatment with amylin and leptin 
actually appears to restore leptin sensitivity in leptin-resistant DIO rats (Roth et al., 
2008). When co-treatment is extended to 28 days, DIO-prone rats show a marked 
decrease in food intake, which results in loss of body weight and a reduction of fat 
mass; this is significantly greater than in pair-fed control rats (Trevaskis et al., 2008). 
Therefore, these results suggest that co-administration of amylin and leptin not only 
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decreases food intake, but also increases energy expenditure with a shift toward fat 
utilization rather than carbohydrate (Trevaskis et al., 2008). 
 
Similar effects have also been observed in humans. The amylin analogue pramlintide 
produce significant reductions in body weight and food intake when administered 
alone in obese humans (Hollander et al., 2004, Smith et al., 2007), but is even more 
effective when combined with the leptin analogue metreleptin (Roth et al., 2008).  
The mechanism underlying the interaction of these two hormones is not fully 
understood. However, it has been suggested that amylin and leptin act via common 
neuronal pathways (Turek et al., 2010). While it cannot be ruled out at this time, the 
AP does not appear to be the primary site of this interaction, because single injections 
of leptin do not enhance the cFos expression induced by amylin in the AP (Turek et 
al., 2010). Instead, evidence points to the VMH as a potential site of interaction for 
amylin and leptin. Amylin treatment restored leptin-sensitivity in DIO rats, as 
substantiated by an increase in leptin-induced pSTAT3 within the VMH (Roth et al., 
2008, Turek et al., 2010). Amylin administration over 7 days also enhanced the 
pSTAT3 response to leptin in the VMH of lean rats (Cole et al., 2007, Trevaskis et al., 
2008). Leptin binding, as determined by receptor autoradiography in the rat brain, was 
increased in the ARC and VMH by combination treatment with amylin and leptin, 
and it was also increased by amylin alone in the VMH and the DMH (Turek et al., 
2010). Furthermore, amylin knockout mice exhibit reduced leptin receptor expression 
and attenuated leptin-induced pSTAT3 activity in the hypothalamus, suggesting an 
important role of amylin for normal leptin signaling, and potentially for the proper 
development of the leptin system (Roth et al., 2010, Trevaskis et al., 2010b, Turek et 
al., 2010).  
 
1.6 Histamine and hypothalamus 
 
Another network thought to be involved in the control of food intake and body weight 
is the histaminergic system. Histamine is produced both in the periphery and in the 
brain, but only histamine produced centrally can act in the brain because circulating 
histamine is not able to penetrate the BBB.  
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Central histamine is produced exclusively by neurons in the tuberomamillary nucleus 
of the hypothalamus (TM) and surrounding areas (Wada et al., 1991). Histaminergic 
neurons arising from the TM receive inputs mainly from the limbic system, and 
project widely throughout the brain (Panula et al., 1984, Watanabe et al., 1984, 
Airaksinen and Panula, 1988, Inagaki et al., 1988, Ericson et al., 1991). Studies in rats 
have shown that physiological central histamine release depends on a circadian 
rhythm and gradually increases during the second half of the light period (Mochizuki 
et al., 1992), reaching its maximum during the active (dark) phase, i.e. when animals 
are eating (Morimoto et al., 2001). Hypothalamic histamine is also released in 
response to feeding (Valdes et al., 2005). This effect is enhanced after a 24-hour fast 
in rats allowed to eat for 15 minutes (Itoh et al., 1991). Interestingly, histamine 
release increased not only during actual eating but also during food presentation, i.e. 
when food was covered and placed in the cage for 15 minutes (Itoh et al., 1991). 
Furthermore, taste information activates hypothalamic histamine release via the 
chorda tympani. For example, oral administration of sweet solutions such as sucrose 
(caloric) or saccharin (non-caloric) produced a decrease in histamine release, whereas 
oral administration of NaCl and HCl induced a significant increase in histamine 
release in freely-moving (Treesukosol et al., 2005) but also in anesthetized rats 
(Treesukosol et al., 2003).  
 
In addition to its effects on histamine release, feeding has also been found to modulate 
the level of the histamine H1 receptor expression; whole-brain H1 receptor 
concentration is inversely correlated with voluntary food intake in rats (Haq et al., 
1996). Three different types of histamine receptors are expressed in the brain (Deng et 
al., 2010). The H1 and H3 histamine receptors are thought to be involved in the 
control of food intake, while H2 receptors mediate other histamine function (Brown et 
al., 2001). Food intake is suppressed by either activation of the histamine H1 receptor 
or by inhibition of the histamine H3 autoreceptor (Sakata et al., 1997, Morimoto et al., 
1999). H3 autoreceptor activation reduces histamine release from its nerve terminals, 
and thioperamide, which blocks the H3 receptor, increases histamine release and 
reduces food intake when infused into the third cerebroventricle (Ookuma et al., 
1993). 
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This research project focused on the central histamine H1 receptor, which seems to 
play an important role in feeding control (Sakata et al., 2003). The relevance of the 
H1 receptor was first discovered after observations that some antidepressants and 
antipsychotic drugs produced side effects like appetite stimulation and weight gain in 
humans (Kalucy, 1980, Russ and Ackerman, 1988). It was then discovered that these 
drugs have H1 receptor blocking activity (Hill and Young, 1978, Taylor and 
Richelson, 1980). Histamine H1 receptors are expressed widely throughout the brain, 
but especially within the hypothalamus, with a very high density in the VMH (see 
Fig. 1.2), and more moderate distribution in the DMH and PVN (Palacios et al., 
1981).  
 
 
Figure 1.2: Histamine H1 receptors density in the hypothalamus (Palacios et al., 
1981). The darker the shading indicates the higher the H1 receptor density in the 
individual areas; ARC: arcuate nucleus; DMH: dorsomedial hypothalamus; 
VMH: ventromedial hypothalamus; dm: dorsomedial, c: central, vl: 
ventrolateral part of the VMH 
 
Activation of central H1 receptors by histamine or H1-agonist administration leads to 
a suppression of food intake, whereas blockade of the H1 receptors results in 
hyperphagia and ultimately in obesity (Fujise et al., 1993, Sakata et al., 2003), (Itowi 
et al., 1988, Lecklin et al., 1998). Similarly, when the histamine concentration is 
elevated by peripherally injecting L-histidine, a precursor of histamine which is able 
to penetrate the blood brain barrier, food intake is decreased as well (Morimoto et al., 
2001).  
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There are two established methods that reliably abolish the effect of H1 receptors: 
administration of H1 receptor antagonists (Mercer et al., 1994) and use of the H1 
receptor knock out (H1rKO) mice. H1rKO mice act as a good research model to 
investigate the functional role of H1r deficiency. Another, though rather unspecific, 
way to inhibit H1 receptor function, is by using α-fluoromethylhistidine (FMH), 
which blocks histamine synthesis by irreversibly inhibiting histidine decarboxylase, 
the enzyme that converts histidine to histamine. As a consequence, H1 receptors are 
not activated. While all models have been commonly used to investigate the role of 
the histaminergic system in the control of eating, FMH is currently not available on 
the market. 
 
1.7 H1rKO mouse model 	  
Treatment with histamine H1 receptor agonists might be an effective and novel 
approach of therapy against obesity and related metabolic disorders (Masaki et al., 
2004). For that reason, a better understanding of H1 receptor function is necessary. 
Therefore we used H1rKO mice to investigate the role of the histamine H1 receptors 
in the control of eating in the current study. The H1rKO mouse is an excellent model 
to investigate the specific function of the H1 receptor and its interaction with 
hormones that control energy homeostasis and feeding behavior. 
 
H1rKO mice show a significantly higher growth rate and body weight compared to 
WT mice from about 6 months of age, and they exhibit higher plasma leptin and 
insulin levels when tested at 48 weeks of age (Masaki et al., 2001b, Masaki et al., 
2004). Another study in our laboratory showed that H1rKO mice demonstrate 
significantly higher body weight already by the age of 12 weeks (Mollet et al., 2001). 
This indicates that histamine may be involved in aging-related obesity (Tsuda et al., 
2002, Masaki et al., 2004). It has also been shown that prior to the onset of obesity, 
H1rKO mice exhibit an altered circadian rhythm, which leads to abnormal feeding 
behavior relative to WT controls (Masaki et al., 2004). Moreover, H1rKO mice show 
increased locomotor activity especially during the early portion of the light phase, but 
decreased exploratory behavior and more frequent defecation and urination in a new 
environment (Inoue et al., 1996, Masaki et al., 2004). Because it is known that 
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disturbances in the circadian feeding rhythm are a risk factor for the development of 
obesity, such abnormalities in the H1rKO mice may perhaps contribute to their obese 
phenotype (Beck et al., 1990, Fukagawa et al., 1992, Murakami et al., 1995). 
 
An interesting feature of the H1rKO mice model is the decreased responsiveness to 
certain hormones that control food intake. Acute amylin (5 and 20μg/kg) and leptin 
(1.3mg/kg) administration in H1rKO mice results in a markedly attenuated anorectic 
effect compared to WT controls (Morimoto et al., 1999, Morimoto et al., 2000, Mollet 
et al., 2001), but this is not observed following CCK (20μg/kg) administration 
(Morimoto et al., 1999, Morimoto et al., 2000, Mollet et al., 2001); hence, the effect 
seems specific to only certain hormones involved in feeding control. Further, H1rKO 
mice treated continuously with leptin over 7 days, either centrally or peripherally, also 
demonstrate decreased leptin sensitivity, in that they exhibit blunted body weight loss 
and less food intake reduction compared to wild type mice (Masaki et al., 2004). 
H1rKO mice also show a decreased cFos response in the hypothalamus following 
leptin injection (Masaki et al., 2004); these results do not, however, indicate if this 
leptin resistance in the H1rKO mice is a result of a defective leptin receptor function 
or of a disruption in the networks downstream of the leptin receptor.  
 
1.8 Interaction between amylin, leptin and histamine 	  
Based on these findings, H1 receptors and the histaminergic system appear to play an 
important role for the control of feeding, and they seem to be specifically involved in 
the mediation of the individual effects of leptin and amylin. Here, we hypothesized 
that the synergistic interaction that exists between amylin and leptin (Osto et al., 
2007, Roth et al., 2008, Roth et al., 2010, Trevaskis et al., 2010a, Turek et al., 2010) 
may also depend on the histaminergic system, and specifically on H1-receptor-
mediated effects. 
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Figure 1.3: This dissertation begins to explore the possible link between the 
central histaminergic system and amylin and leptin synergy. Experimental 
evidence points to the VMH as a potential key locus for both histamine action 
and the interaction between amylin and leptin 
 
The evidence outlined above supports the idea that the histaminergic system may be 
an important player in the synergistic effects of amylin and leptin on body weight and 
food intake. As mentioned, H1rKO mice exhibit an attenuated anorectic response to 
amylin (Mollet et al., 2001). Further studies have shown that amylin’s inhibitory 
effect on food intake is markedly reduced when the specific H1 receptor antagonists 
chlorpheniramine (CPA) or pyrilamine (PYR) are administered directly into the VMH 
in rats (Mollet et al., 2003). Additional findings that support a link between amylin 
and histamine demonstrate that blockade of histamine release by H3 agonists reduces 
amylin’s anorectic effect (Lutz et al., 1996) and that amylin-expressing neuronal 
fibers colocalize with histamine-producing neurons within the TM, suggesting that 
amylin function may perhaps involve an interaction with the histamine system (D'Este 
et al., 2001). 
 
In regards to the link between leptin and histamine function, we already mentioned 
that mice deficient in H1 receptors show decreased responsiveness to both acute and 
chronic leptin treatment (Morimoto et al., 2000, Mollet et al., 2001, Morimoto et al., 
2001, Masaki et al., 2004). Moreover, Morimoto and colleagues showed that the 
leptin-induced suppression of food intake is abolished when mice or rats were 
injected with FMH to block histamine production (Morimoto et al., 1999, Toftegaard 
et al., 2003). Further, leptin may facilitate hypothalamic histamine release 
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(Yoshimatsu et al., 1999, Morimoto et al., 2000) because hypothalamic histamine 
levels increase immediately after leptin (1.3mg/kg i.p.) administration and remain 
elevated for up to 4 hours (Morimoto et al., 2000), hence at a time when leptin 
typically exerts its anorectic action. 
 
Finally, as summarized above, the synergistic relationship between amylin and leptin 
treatment is potentially a very powerful therapeutic tool to treat obesity. Amylin 
enhances or restores the efficacy of leptin treatment in lean and obese rodents, as well 
as in humans. Using pSTAT3 as a marker for leptin receptor activation, it appears that 
the VMH may be a critical site where amylin treatment enhances leptin signaling 
(Roth et al., 2008). Given the high density of H1 receptors in the VMH (Palacios et 
al., 1981), and the known effects of histamine in the VMH on food intake (Sakata et 
al., 1988, Ookuma et al., 1993, Mollet et al., 2003, Magrani et al., 2004), it seems 
plausible to propose that the histaminergic network acting in the VMH may contribute 
to the interaction observed between amylin and leptin.  
 
Based on these data, we suggest that these three components, amylin, leptin, and 
histamine, interact at the level of the VMH to promote a decrease in food intake and 
body weight. We therefore hypothesized that the histaminergic system, and 
specifically H1 receptors, may be a critical component contributing to the synergistic 
relationship between amylin and leptin. 
 
1.9 Approach and hypothesis 	  
The main goal of this dissertation was to determine the role of the H1 receptor in 
mediating the effects of acute amylin and leptin administration, both independently 
and in combination, on food intake. Additionally, we sought to more thoroughly 
describe the metabolic phenotype of H1rKO mice, which was the animal model used 
for all studies described herein.  
 
1.9.1 Experiment 1: Metabolic phenotyping of H1rKO mice 	  
The first aim was to better characterize the metabolic phenotype of the H1rKO mice. 
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While some general phenotyping had been performed in these mice, some parameters, 
such as body composition and energy expenditure (EE) have not been assessed. We 
therefore measured body composition (i.e. fat mass distribution) via computer 
tomography, energy expenditure (EE) and respiratory quotient (RQ) via indirect 
calorimetry, assessed physical activity (PA), and measured daily and fasting-induced 
food intake (FI) as well as plasma levels of amylin, leptin and insulin, in H1rKO 
compared to WT mice. 
 
1.9.2 Experiment 2: Do mice lacking H1 receptors respond to higher doses of 
amylin?  
 
It is known that H1rKO mice are less responsive to acute amylin (5μg/kg or 20μg/kg) 
treatment (Mollet et al., 2001). Since it was not clear if this also holds true for higher 
doses, our intention was to assess the action of amylin on food intake in a dose-
dependent manner and over a wide dose range in H1rKO compared to WT mice.  
 
1.9.2.1 Does amylin induce cFos activation in the AP of H1rKO mice?  
 
We further wanted to test whether the reduced responsiveness of H1rKO mice to 
single amylin administration is related to a disruption of amylin signaling in the AP or 
in downstream projection sites. To test this, amylin at a dose of 50μg/kg was injected 
intraperitoneally and an immunhistochemical study was conducted to quantify the 
activation of neurons in the AP by visualizing cFos expression.  
 
1.9.3 Experiment 3: Do mice lacking H1 receptors respond to higher doses of 
leptin?  
 
H1rKO mice are also less responsive to leptin at a dose of 1.3mg/kg (Morimoto et al., 
1999, Mollet et al., 2001). Since it is not clear if this is also true for higher doses, the 
intention was to assess the individual action of leptin on food intake in a dose-
dependent manner over a wide dose range in H1rKO compared to WT mice.  
 
Introduction 
	  20 
1.9.3.1 Does leptin induce pSTAT3 activation in the VMH and ARC of H1rKO 
mice?  
 
We further wanted to test whether the reduced responsiveness of H1rKO mice to 
single leptin administration is related to a disruption of leptin signaling within the 
leptin-sensitive brain sites, e.g. the VMH and ARC, or in projection sites. To test this, 
leptin at a dose of 1.3mg/kg was injected intraperitoneally and an 
immunhistochemical study was conducted to assess the function of leptin receptors by 
visualizing pSTAT3 signaling in the VMH and ARC. 
 
1.9.4 Experiment 4: Do mice lacking H1 receptors respond to combined amylin 
– leptin administration? 
 
Because amylin is able to restore leptin’s eating inhibitory effect in leptin-resistant 
rats and humans, and because amylin is able to reinstate leptin-induced pSTAT3 
activity in the VMH of DIO rats (Roth et al., 2008), we wanted to investigate whether 
co-treatment with amylin and leptin is as effective at reducing food intake in H1rKO 
mice as in WT mice. This experiment addressed the potential role of the H1 receptor 
in the mediation of the amylin—leptin interaction.  
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2 Material and methods 
 
2.1 Animals and housing conditions 
  
For all experiments, male C57BL/6J wild type (WT) mice and male histamine H1 
receptor knock out (H1rKO) mice were used. The H1rKO mice were generated by 
homologous recombination (H1rKO; background strain C57BL6) (Inoue et al., 1996). 
The C57BL/6J mice were either taken from our in-house breeding colony or ordered 
from Charles River Laboratories (Sulzfeld, Germany) when additional mice were 
needed; our in-house colony was originally derived from breading pairs supplied by 
Charles River. 
 
Mice were maintained in a temperature-controlled environment (21±2°C), on a 
12h/12h light-dark cycle (lights on at 0100h and off at 1300h). Water and food (see 
section 2.2 for details) were accessible ad libitum, unless otherwise described. 
Animals were habituated to the housing conditions for at least one week prior to the 
start of an experiment. Mice were handled daily for the first 2-4 weeks after their 
arrival with a special desensitization technique (see supplemental section 2.13). Body 
weight was measured every 1-3 days during the entire experimental time period, and 
baseline food intake was measured weekly or, when the mice were in experiments, 
more frequently at specific time points.  
 
All experiments were approved by the Veterinary Office of the Canton of Zurich, 
Switzerland. 
 
2.1.1 Housing conditions in Makrolon cages 	  
For most experiments, animals were group housed in Makrolon cages (2-5 
mice/cage). Occasionally, some mice were single housed due to aggressive behavior.  
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2.1.2 Housing conditions in hanging wire-mesh cages 	  
For some experiments in which individual food intake was measured, mice were 
individually housed in hanging, stainless steel wire-mesh cages (24 × 25 × 18cm). 
 
2.1.3 Housing conditions in the metabolic cages 	  
For some feeding trials and for all experiments measuring energy expenditure, mice 
were individually housed in transparent plastic metabolic cages (24.2 × 16 × 18.4cm) 
containing wood shavings, paper for nesting and a small carton house. The cages 
allow the measurement of several metabolic parameters, including oxygen 
consumption, carbon dioxide production, food and water intake (DietMax, AccuScan 
Instruments, Inc. Columbus, Ohio 43228, USA). The animals received the standard 
chow food (see section 2.2) of a comparable composition in powder form as they had 
received the weeks before in the hanging wire mesh cages. In order to accurately 
measure physical activity, houses and nesting material were removed during such 
testing periods. 
 
The water bottles and the food cups were placed on scales for continuous monitoring 
of drinking and eating. Water and food intake were measured every five minutes 
using Integra ME Version 2.21 (AccuScan Instruments), as described in detail in 
section 2.5. 
2.2 Experimental diets 
 
The Standard pelleted chow (D3436, Extrudate) and the Powered chow diet (D3433, 
GLP) had the same composition and were produced by Provimi Kliba AG, 
Kaiseraugst, CH. 
Material and methods 
	  23 
Major Nutrients: 
Dry matter    88.0% 
 Crude protein    18.5% 
 Crude fat      4.5% 
 Crude fiber      4.5% 
Crude ash      6.3% 
NFE     54.2% 
Starch     35.0% 
Metabolizable energy   13.2MJ/kg 
 
2.3 Amylin and leptin 
 
Amylin (Bachem AG, Bubendorf, CH) was diluted in 0.9% NaCl (Fresenius Kabi 
AG, Stans, CH) in various concentrations. Recombinant murine leptin (PeproTech EC 
Ltd, London, UK) was diluted in aqua ad injectabila (Ampuwa, Fresenius Kabi AG) 
in various concentrations. All peptides were freshly dissolved immediately before the 
start of an experiment and then kept chilled on ice until injection.  
 
2.4 Feeding test procedure 
 
Prior to experiments in which food intake was measured, mice were fed either ad 
libitum (Experiment 2a) or fasted for 6 hours prior to injection at dark onset 
(Experiment 2b, 3 and 4). For each feeding trial, WT and H1rKO mice were randomly 
divided into four (Experiment 2a, 3 and 4) or five (Experiment 2b) treatment groups, 
respectively (see section 2.11). A crossover design was used with randomized order 
of treatment so that each animal received all treatments and acted as its own control. 
There was at least one day between two trials to allow for animal recovery and 
clearance of exogenously administered substances. Food was presented just after the 
injections at dark onset (1300h). Food intake was typically measured one, two and 
four hours after injection, as described below. 
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2.5 AccuScan system in the metabolic cages 
 
The measurement of the gas exchange was achieved by using an Open Circuit 
Calorimetry system (AccuScan Instruments). The plastic cages were equipped with 
tight-fitting covers and an inserted pump and gas analyzers, which enabled the 
measurement of the oxygen (O2) and carbon dioxide (CO2) content of air flowing in 
and out of the cage. Changes of the gas composition of the in-flowing and out-flowing 
air were indicative of oxygen consumption and carbon dioxide production, 
respectively. The oxygen analyzer utilized a Zirconia sensor, the carbon dioxide 
analyzer used a dual beam sensor. Both analyzers were connected to the individual 
cages and transmitted the measured data to the metabolic integrating system, which 
also received the data from the food and water scales. Oxygen and carbon dioxide 
concentrations of each cage were measured for 30 seconds every five minutes. Before 
the start of an experiment, the analyzers were calibrated; the percentage of oxygen in 
the room air was set to 20.94%, and by using a 12-hour-fasted WT mouse, the 
respiratory quotient was adjusted to approximately 0.7. From the measured data, 
several physiological parameter were calculated by the fusion software (Integra ME 
Version 2.21, AccuScan Instruments) including O2 consumption (VO2), carbon 
dioxide production (VCO2), energy expenditure (EE), and respiratory quotient (RQ): 
 
Oxygen consumption: 
 
VO2 [ml/kg/min] =  
 
 
 %N2 Ref = 100 − (%O2 Ref + %CO2 Ref) 
 V1 = %N2 Ref × %O2 Change 
 V2 = %N2 Ref × (%O2 Change − %CO2 Change) 
 
Carbon dioxide production: 
  
VCO2 [ml/kg/min] =    
 
Flow [ml/min] × (V1 + V2) 
100 × %N2 Ref × Weight [kg] 
Flow [ml/min] × %CO2 Change 
Weight [kg] × 100 
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The VCO2 and VO2 values were used to calculate energy expenditure according to 
Weir (Weir, 1990): 
 
 EE [kcal/kg/min] =  
 
The respiratory quotient was used to identify the preferred source of oxidation; RQ 
equals 1.0 if carbohydrates are used as energy source; RQ equaling 0.7 indicates if fat 
is used as the sole energy source: 
 
 RQ = 	  
2.6 Activity measurement 
 
The physical activity of the mice was measured using a frame of horizontal infrared 
beams. The number of beam breaks was quantified as a direct measure of activity. 
 
2.7 Blood sampling 
 
Prior to blood sampling, mice were food-deprived for 4 hours. Blood sampling was 
started at dark onset (1300h), and was conducted as a terminal experiment. Mice were 
deeply anesthetized with pentobarbital (pentobarbital sodium, 80mg/kg i.p., 
Kantonsapotheke Zurich, CH), immediately following which the jugular vein was 
severed with a sharp scalpel, blood was collected in a 500μl EDTA-coated tube 
(Microvette 500K3E, Sarstedt AG & Co., Nümbrecht, Germany) and mixed with 5μl 
of a protease inhibitor cocktail (Aprotinin, P2714 Protease Inhibitor Cocktail, Sigma-
Aldrich, Buchs SG, CH) to stop the enzymatic degradation of peptide hormones. The 
blood remained cooled on ice until it was centrifuged for 10 minutes at 1000g. Plasma 
was transferred to clean Eppendorf tubes and stored at - 20°C until use.  
 
2.8 CT scan for body composition analysis 
 
Body adiposity was determined in sacrificed animals by computerized tomography 
3.9 × VO2 + 1.1 × VCO2 
1000 
VCO2 
 VO2 
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(CT) using the La Theta LCT-100 (Aloka CT, Tokio, JP; for validation details, please 
see (Hillebrand et al., 2010)). The X-ray source tube voltage was set at 50kV with a 
constant 1mA current. The ice-cooled carcasses were placed supine in Plexiglas 
holders with an inner diameter of 48mm, resulting in a pixel resolution of 100µm. 
First, a sagittal image of the entire animal was made to ensure proper placement in the 
holder and to set the scan area, which was defined from diaphragm to hip joints. La 
Theta 2.10-Aloka software was used to calculate the volumes of adipose tissue, bone, 
air, and remaining tissue, using differences in X-ray density. Intraabdominal and 
subcutaneous adipose tissues were distinguished based on the detection of the 
abdominal muscle layers (see Figure 3.1; Kobayashi et al., 2002). This automated 
classification often required manual image-by-image correction. The amount of 
adipose tissue located between the diaphragm and the hip joints was measured to 
compare subcutaneous and intraabdominal body fat content in both 
genotypes. Adipose tissue weights were then computed using the commonly used 
density factor of 0.92g/cm3 (Hill et al., 2007) to determine the absolute values in 
gram. 
 
 
Figure 2.1: Abdominal cross section of a H1rKO mouse; subcutaneous fat 
(yellow), intraabdominal fat (purple), lean tissue (turquoise) 
 
2.9  Hormone analysis 
 
Amylin, leptin and insulin were measured using plasma samples and the hormone kit 
Milliplex Mouse Endocrine Immunoassay MENDO-75K-03 (Millipore Corporation, 
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Billerica, MA, USA). The frozen plasma samples were thawed, mixed and 
centrifuged at 3000g for 5 minutes. The assay was based on conventional sandwich 
assay technology and permitted simultaneous detection of multiple hormones from a 
single sample. Briefly, according to the manufacturer’s protocol, the microspheres 
were incubated with standards, controls and the plasma samples (10μl) in a 96-well 
microtiter filter plate on a plate shaker overnight (16-18 hours) at 4°C. After 
incubation, the plate was washed three times with assay buffer (200μl/well) to remove 
excess reagents (by vacuum between each rinse), followed by the addition of the 
detection antibody (50μl/well). Then the plate was placed again on the plate shaker 
for 60 minutes at room temperature, after which 50μl streptavidin-phycoerythrin was 
added to each well containing 50μl of detection antibody cocktail and incubated for 
an additional 30 minutes. After a final washing step (3 rounds of washing and fluid 
removal by vacuum filtration), the beads were re-suspended in buffer (100μl of sheath 
fluid) and the plate was analyzed using the Bio-Plex analyzer powered by xMAP 
Luminex technology (Bio-Rad Laboratories Inc., Reinach BL, CH) to determine the 
concentration of amylin, leptin, and insulin. Data were analyzed by Bio-Plex 
Manager™ software versions 4.0 and 5.0 (Bio-Rad Laboratories Inc.) 
 
2.10 Perfusion and immunohistochemistry 
 
Two perfusion protocols were used for detection of pSTAT3 and cFos 
immunoreactivity in mouse brain tissue. 
 
2.10.1 Perfusion protocol for pSTAT3 	  
Mice were anesthetized with pentobarbital intraperitoneally, and perfused 
intracardially (10ml/min) with 0.9% NaCl for 90 seconds, followed by ice-cold 2% 
paraformaldehyde (Sigma-Aldrich, pH 7.2) in potassium-phosphate-buffered saline 
(KPBS) for 120 seconds via the ascending aorta. Following perfusion, the brain was 
removed by dissection, post-fixed in 2% paraformaldehyde solution for 2 hours, and 
cryoprotected in 20% sucrose KPBS solution for 36-48 hours at 4°C. 
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2.10.2 Perfusion protocol for cFos 	  
Mice were anesthetized with pentobarbital intraperitoneally, and perfused 
intracardially (10ml/min) with ice-cold 0.1M phosphate buffer (PB, Sigma-Aldrich, 
pH 7.2) for 90 seconds, followed by ice-cold 4% paraformaldehyde in 0.1M PB (pH 
7.2) for 120 seconds via the ascending aorta. Following perfusion, the brain was 
removed by dissection, and post-fixed in 4% paraformaldehyde solution for 2 hours, 
and cryoprotected in 20% sucrose PB solution for 36-48 hours at 4°C. 
 
2.10.3 Brain tissue processing 	  
The brains were frozen in chilled Hexane (Fluka Chemie GmbH, Buchs SG, CH) on 
dry ice, and stored at -20°C until sectioned coronally using a cryostat (Leica 
CM3050S, Nussloch, Germany). Twenty-micrometer sections collected from the 
forebrain (containing VMH and ARC) and the hindbrain (containing AP and NTS; 
according to Paxinos and Watson, 2007) were thawed mounted onto adhesion glass 
slides (Superfrost Plus, Gerhard Menzel GmbH, Braunschweig, Germany). 
 
2.10.4 Protocol for pSTAT3-immunostaining 
 
Frozen slides were first brought to room temperature and then rinsed in 0.02M KPBS 
for 10 minutes. Slides were subjected to the following antigen-retrieval and blocking 
steps, with rinsing in 0.02M KPBS between each step: 0.3% NaOH + 0.3% H2O2 in 
KPBS for 20 minutes, 0.3% glycine in KPBS for 10 minutes, 0.03% sodium dodecyl 
sulfate (SDS) in KPBS for 10 minutes, and blocked in 4% natural donkey serum 
(NDS, Jackson ImmunoResearch Inc., Newmarket, Suffolk, UK) with 0.4% Triton 
and 1% bovine serum albumin (BSA) in KPBS for 20 minutes. The primary antibody 
(1:500, Phospho-Stat3 (Tyr705) (D3A7) XPTM Rabbit mAb, Cell Signaling 
Technology Inc., Denver MA, US) was added to the blocking solution with 1% NDS 
(Jackson ImmunoResearch Inc.), 0.4% Triton and 1% BSA in KPBS and incubated 
for 48 hours at 4°C. Then, sections were washed in KPBS for 45 minutes, incubated 
with donkey anti-Rabbit Alexa-555 IgG (H+L) (1:100; Invitrogen AG, Basel, CH) in 
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1% NDS with 0.3% Triton in KPBS for 2 hours at room temperature. As a final step, 
slides were rinsed in 0.02M KPBS for 45 minutes before being covered-slipped with 
Citifluor™ (Glycerol/PBS solution AF1; Citifluor Ltd., London, UK).  
 
2.10.5 Protocol for cFos-immunostaining 
 
Frozen slides were first brought to room temperature and then rinsed in phosphate-
buffered saline (PBS; pH 7.4) containing 0.1% phosphate-buffered saline with Triton 
X-100 (PBST). Slides were first incubated in NDS (1.5% in 0.3% PBST; Jackson 
ImmunoResearch Inc.) for 2 hours, followed by a 48-hour incubation in polyclonal 
rabbit anti-cFos (1:5,000 in 0.3% PBST; AB-5, Oncogene) at 4°C. Following 50 
minutes of rinsing in 0.1% PBST, sections were incubated in biotinylated donkey 
anti-rabbit IgG (1:400 in 0.3% PBST; Jackson ImmunoResearch Inc.) for 90 minutes 
at room temperature. Slides were rinsed with 0.1% PBST for 30 minutes, and then 
incubated for 90 minutes in avidin-biotin-peroxidase complex (1:100 in 0.3% PBST, 
Vectastain ABC kit, LINARIS GmbH, Dossenheim, Germany). Sections were then 
rinsed once with 0.1% PBST for 10 minutes and once in 
Tris(hydroxymethyl)aminomethane-hydrochlorid acid (Tris-HCl) for 10 minutes 
before being incubated in 3,3’-Diaminobenzidine Tetrahydrochlorid (DAB, Sigma-
Aldrich) solution for 8 minutes to visualize cFos-positive cells. The DAB-solution 
was made in Tris-HCl (0.04% DAB, 0.008% H2O2). After rinsing the slides with Tris-
HCl for 5 minutes and 0.1% PBST for 5 minutes, they were dehydrated in graded 
alcohol (50%, 75%, 95%, 100%) and immersed in xylol for 5 minutes each before 
being cover-slipped with Entellan (Merck KGaA, Darmstadt, Germany). 
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2.11 Description of individual experiments 
 
2.11.1 Experiment 1: Metabolic phenotyping of H1rKO mice 
 
2.11.1.1 Experiment 1a 	  
In a first study, C57BL/6J WT mice (BW: 32 ± 4g; n=6) and H1rKO mice (BW: 37 ± 
4g; n=8) at an average age of 6 months were used for blood sampling. Plasma 
samples were used to perform hormone analysis for leptin, insulin and amylin. 
Following blood sampling and sacrifice, the carcasses were used for CT scan to assess 
body composition by estimating the amount of intraabdominal and subcutaneous body 
fat.  
 
2.11.1.2 Experiment 1b 	  
In a second study, a separate group of WT mice (BW: 28 ± 2g; n=8) and H1rKO mice 
(BW: 31 ± 3g; n=8) at an average age of 5 months were housed in metabolic cages to 
perform metabolic baseline measurements including EE, RQ, physical activity, 24-
hour food intake and food intake subsequent to 6-hour fasting. After an adaptation 
period of 5 days in the metabolic cages, the 24-hour data were recorded by the 
AccuScan system over three days; results are presented as the average of the three 
days. As an additional experiment to determine the feeding behavior of WT and 
H1rKO mice after a short period of fasting, access to the food hoppers was blocked 
for 6 hours from 0700h until dark onset (1300h). Food intake was measured 
automatically from dark onset and data for 1, 2 and 4-hour food intake were analyzed 
using the Integra program. 
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2.11.2 Experiment 2: Effects of amylin on food intake and cFos induction in 
H1rKO mice 
 
2.11.2.1 Experiment 2a in ad libitum fed mice 	  
WT mice (BW: 28 ± 2g; n=12) and H1rKO mice (BW: 33 ± 4g; n=11) at an average 
age of 5 months were used to investigate the role of H1 receptors in amylin’s 
anorectic effect by assessing food intake following administration of different amylin 
doses. 
 
Mice were individually housed in hanging wire mesh cages for 2 weeks prior to the 
start of the experiment to allow for adaptation to the new, individual housing 
conditions. During this time, mice were taken out of the cages periodically for body 
weight measurement and adaptation to the restraint position necessary for 
intraperitoneal injections. Mice had free access to water and chow, except at the day 
of experiment for about 15-30 minutes during injections. 
 
The experiment was conducted in a crossover manner consisting of 4 trials in which 
each mouse was exposed to each treatment dose. On experimental days, food was 
removed from the cages 15-30 minutes before the start of each trial. Mice were 
injected with saline or amylin (5, 20 or 50µg/kg; i.p.) just before dark onset (1300h) 
with an injection volume of 0.1ml/10g bodyweight, following which food was 
immediately returned to the cage. Food intake was measured by manually weighing 
the pellets in the food hoppers, trying to avoid contamination by urine and feces. Food 
intake was measured 1, 2 and 4 hours after injection. 
 
Two days after the last feeding trial, non-fasted WT mice (n=12) and H1rKO mice 
(n=6) of the same cohort were injected with either saline or amylin (50µg/kg; i.p.) at 
dark onset (1300h) for the terminal experiment. Just after the injections, food was 
taken out of the cages and mice were anesthetized and perfused two hours later. In 
this particular case, the pSTAT3 perfusion protocol had been used for detection of 
cFos; this did not compromise the detection of cFos immunoreactivity. cFos-positive 
cells were counted in the AP under light microscopy.  
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2.11.2.2 Experiment 2b in 6-hour fasted mice 
 
Because a significant effect of amylin on food intake was not observed in H1rKO 
mice at the doses administered in Experiment 2a, an additional experiment was 
conducted to assess the effect of an additional, higher amylin dose (200µg/kg; i.p.) in 
WT (BW: 28 ± 2g; n=4) and H1rKO mice (BW: 30 ± 1g; n=4) which had an average 
age of 5½ months. These mice were kept in metabolic cages and were adapted to the 
new environment conditions for 7 days before the feeding trials started. Similar to 
Experiment 2a, the experiment was conducted in a crossover manner consisting of 
five trials. 
 
On experimental days, the animals were food restricted for the last 6 hours of the light 
phase (0700-1300h). Immediately prior to dark onset, mice were injected with either 
saline or amylin at a dose of 5, 20, 50 or 200µg/kg (i.p.) with an injection volume of 
0.1ml/10g BW. Following completion of all injections, food was immediately 
returned. Food intake was recorded automatically by the AccuScan system, and 1, 2 
and 4-hour food intake was analyzed with the Integra program.  
 
For the terminal experiment, four WT mice and four H1rKO mice were fasted for 6 
hours prior to receiving an injection of either saline or amylin (50µg/kg; i.p.) at dark 
onset (1300h), and then anesthetized and perfused two hours later. Mice were 
perfused using the cFos perfusion protocol and cFos-positive cells were counted in 
the AP under light microscopy.  
 
2.11.3 Experiment 3: Effects of leptin on food intake and pSTAT3 induction in 
H1rKO mice 
 
The mice used in Experiment 1b for basic metabolic measurements were used in this 
experiment. Wild type mice (BW: 28 ± 2g; n=8) and H1rKO mice (BW: 30 ± 4g; 
n=8)) at an average age of 5 months were used to investigate leptin’s effect on eating 
by assessing food intake following administration of various leptin doses. The 
experiment was performed in a cross over manner consisting of five trials. 
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The mice remained housed in the metabolic cages following Experiment 1b. On 
experimental days, access to food was blocked in the middle of the light phase at 
0700h, and the mice were injected with either saline or leptin (500μg/kg, 1, 5 or 
10mg/kg; i.p.) 2 hours prior to dark onset (1100h). At dark onset (1300h), mice were 
given access to food and food intake was measured for 1, 2 and 4 hours automatically 
by the AccuScan system. Data were analyzed using the Integra program. 
 
In a separate experiment using a different cohort of mice, non-fasted WT mice (BW: 
27 ± 2g; n=5) and H1rKO mice (BW: 32 ± 2g; n=6) were injected with either saline 
or leptin (1.3mg/kg; i.p.) at dark onset (1300h), and then anesthetized and perfused 45 
minutes later. The pSTAT3 perfusion protocol was used for detection of pSTAT3-
positive cells, which were counted in the VMH and ARC from photomicrographs 
obtained under fluorescent microscopy. 
 
2.11.4 Experiment 4: Effects of amylin and leptin co-treatment on H1rKO mice 
 
The same animals as in Experiments 1b and 3 were used to investigate the effect of 
amylin and leptin co-treatment on food intake. The experiment was assessed in a 
crossover manner across four trials testing four different treatment groups: Saline-
saline, saline-amylin, saline-leptin and amylin-leptin. Wild type mice (BW: 28 ± 2g; 
n=8) and H1rKO mice (BW: 30 ± 4g; n=8) at approximately 5½ months of age were 
fasted for the last 6 hours of the light phase (0700-1300h). Two hours prior to dark 
onset (1100h) the mice were injected with saline or leptin (1mg/kg; i.p.). Just before 
dark onset (1300h), the animals were injected with either saline or amylin (50μg/kg; 
i.p.), and access to food was given immediately following the completion of injections 
(see Figure 2.2). Food intake was recorded automatically by the AccuScan system and 
data of 1, 2 and 4-hour-food intake were analyzed using the Integra program.  
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Figure 2.2: Timeline of Experiment 4 
 
2.12 Statistical analysis 
 
All data are expressed as mean ± SEM. In experiments comparing independent 
treatment groups, a 1-factor ANOVA was used to detect statistically significant 
differences between the control saline and the different dose groups, with 
Bonferroni’s Multiple Comparison Test used to determine differences between 
individual groups. When more than two factors were compared (genotype x dose), 
data were analyzed using a 2-factor ANOVA, with Bonferroni’s post-hoc test used to 
determine differences between individual groups. In some cases, the Mann-Whitney 
U test was used for non-parametric comparison of independent groups. A p-value 
<0.05 was considered to be statistically significant. Statistical analyses were 
performed using the GraphPad Prism (version 5.0a, San Diego, CA, USA). 
 
2.13 Supplemental methods 
 
2.13.1 Instruction for mouse handling 
  
When laboratory mice are handled, they typically display defensive behaviors such as 
biting and fleeing from the experimenter; this is very stressful for laboratory animals 
and the experimenter. The goal of the following handling procedure was to decrease 
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or even stop these behaviors, which results in less stress for both animals and 
investigator. Other studies have shown that animal handling improves experimental 
outcome (Ryabinin et al., 1999); this has been previously established in our laboratory 
by Becskei (Becskei et al., 2009). 
 
Based on personal communication with Dr. Gustavo Pacheco Lopez (Physiology and 
Behavior Laboratory, ETH Zurich), who applies the so-called meatball technique in 
mice intended for brain cannulation, this specific handling technique was extended by 
a self-invented desensitization program. The handling procedure is based on the 
desensitization principle established by Joseph Wolpe (Wolpe, 1961, 1963, 1969).  
 
The mice were handled daily. The investigator begins by wearing thick gloves to 
avoid being bitten. One hand firmly holds the mouse’s tail to secure the mouse on a 
cage lid grid. With the other hand, the investigator carefully strokes the animal’s fur, 
which will trigger the mouse to try to bite in defense. A pencil tip can also be used to 
stroke the mouse to provide more protection in the first days of handling. Contact 
with the animal is maintained as long as it continues biting, but only limited pressure 
should be applied on its body. As soon as the mouse ceases to bite, the finger or 
pencil should be removed. The mouse will learn quickly that as long as it is biting, the 
object is not going to be removed. The initial days require much patience. Upon 
successfully learning not to bite, the mouse can be returned to the cage, and practice 
will continue next day again.  
 
With daily handling the mice will stop biting, and after approximately one week the 
mice are noticeably calmer. It is observable that the mice urinate and defecate less, 
and progressively, cease to show this sign of stress altogether. The intensity of touch 
can be increased when the mice tolerate gentle touches. The more time that is given to 
them to accept handling, the better they learn not to be afraid. As a next step, e.g. 
when i.p. injections are practiced, the mice will start to be stressed again, because of a 
new situation. Again, it is possible for them to get used to being held in the back 
restraint position and tolerate the pain. Therefore it is important to proceed step by 
step and not to overload the animals. 
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For longer experiments, where it is known that the animal will stay under the 
researcher’s care for several weeks, it may help to spend more time with the animals. 
For instance, the first contact with the mice can be to simply place a gloved hand into 
the cage without doing anything additional. The animals will then begin to investigate 
and smell the fingers, and eventually will try to climb up the investigator’s arm. At 
this point when the mice are used to the hand sitting in the cage, it is much easier to 
retrieve them from the cage.  
 
Based on my personal experience with handling mice in this manner, I conclude that 
mice are quite intelligent and learn quickly. The transformation of the mouse behavior 
from the start to the end of an experiment was truly amazing. I highly recommend 
taking the additional time to handle mice in this way. It really benefits the mice and 
the experiment. 
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3 Results 	  
3.1 Experiment 1: What are the characteristics of H1rKO mice? 
3.1.1 Body weight and fat distribution 
 
In the first experiment, we sought to further phenotype the H1rKO mice. Body weight 
data at weaning were not available. The mice were on average 19 weeks (4½ months) 
old when recruited for this experiment. They had free access to standard chow and 
water, and were group housed with 2-5 mice per Makrolon cage. Figure 3.1A shows 
that the body weight of H1rKO mice was significantly higher (p<0.001) than the WT 
mice for the entire observation time leading up to the final sampling day (Fig. 3.1B). 
Blood sampling was performed and body composition was analyzed at about 6 
months of age. 
 
 
Figure 3.1: Body weight in WT mice (n=6) and H1rKO (n=8) over 40 days (A) 
and on the final sampling day (B). All data are expressed as mean ±SEM, 
symbols denote significant differences between the two genotypes; **p<0.01, 
***p<0.001 
 
To assess body composition of the two genotypes, body fat was measured using CT 
scan. The amount of adipose tissue located between the diaphragm and the hip joints 
was measured to compare subcutaneous and intraabdominal body fat content in both 
genotypes. Figure 3.2 shows that the H1rKO mice had significantly more 
subcutaneous (p<0.05) and intraabdominal (p<0.05) fat than WT mice, which was 
consistent with the higher body weight in H1rKO mice. To account for the higher 
A	   B 
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body weight in H1rKO mice, if fat mass was normalized to total body weight, H1rKO 
mice still exhibited a higher ratio of fat mass to total weight compared to WT controls 
(data not shown), confirming increased adiposity. 
 
 
 
Figure 3.2: Subcutaneous (A) and intraabdominal (B) fat mass in WT (n=6) and 
H1rKO (n=8) mice. All data are expressed as mean ±SEM. The symbol denotes 
significant differences between the two genotypes; *p<0.05 
 
3.1.2 Circulating hormones 
 
Circulating hormones were measured to characterize the baseline level of satiation 
and adiposity hormones in H1rKO mice compared to WT mice after a fasting period 
of 4 hours. Figure 3.3 shows that H1rKO had significantly higher leptin levels 
(p<0.05) than WT and demonstrated a tendency for higher levels of amylin and 
insulin. These results correspond with elevated body weight and body adiposity 
observed in the H1rKO mice. 
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Figure 3.3: Fasting baseline insulin (A), amylin (B) and leptin (C) blood levels in 
WT (n=6) and H1rKO (n=8) mice at an age of 6 months. Individual data are 
shown and all data are also expressed as mean ±SEM. The symbol denotes a 
significant difference between the two genotypes; *p<0.05 
 
3.1.3 Energy expenditure and activity 	  
To assess metabolic parameters in H1rKO mice compared to WT mice, energy 
expenditure (EE), respiratory quotient (RQ), food intake (FI) and physical activity 
(PA) were measured over 3 days using open circuit indirect calorimetry. Average data 
over the three days are presented. As shown in Figure 3.4A, the average EE was not 
significantly different between the light and dark phase, nor was there a clear 
genotype effect. However, the H1rKO showed a tendency toward lower EE. Two-way 
ANOVA detected an overall light phase effect (p<0.01) but no genotype effect for RQ 
(Fig. 3.4B). Follow-up analysis in both genotypes showed a tendency to decreased 
respiratory quotient during the light phase, but the effect was not significant. 
A B C 
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Figure 3.4: Energy expenditure (A) and average respiratory quotient (B) in WT 
(n=8) and H1rKO (n=8) mice during dark and light phase. All data are 
expressed as mean ±SEM 
 
Figure 3.5 shows the physical activity in WT and H1rKO mice during the dark and 
light cycle. There was no genotype effect but overall markedly lower physical activity 
during the light phase (p<0.01). 
 
 
Figure 3.5: Physical activity in WT (n=8) and H1rKO (n=8) mice during dark 
and light phase. All data are expressed as mean ±SEM 
 
3.1.4 24-hour food intake in WT and H1rKO mice 
 
To investigate the baseline feeding behavior in H1rKO mice, cumulative 24-hour 
food intake was measured over three days, and the average of these three days was 
analyzed. Two-way ANOVA did not detect a genotype effect but a very clear overall 
light phase effect (p<0.01; Fig. 3.6). 
A B 
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Figure 3.6: Average cumulative FI during the dark and light phases measured 
over 3 days in WT (n=8) and H1rKO (n=8) mice. All data are expressed as mean 
±SEM 
 
Analysis of hourly food intake (Fig. 3.7) again showed no genotype effect but a clear 
effect of time (p<0.001). The H1rKO mice showed a tendency toward higher FI 
compared to WT mice in the first three hours after the onset of dark.  
 
 
Figure 3.7: Average hourly FI during 24 hours in WT (n=8) and H1rKO (n=8) 
mice. All data are expressed as mean ±SEM. The black bar indicates the dark 
phase; time point 0=1300h; 12=0100h 
 
3.1.5 Fasting induced food intake 
 
To test whether the tendency of increased food intake in H1rKO in the first hours 
after dark onset can be augmented, the animals were fasted for 6 hours prior to dark 
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onset in the next experiment. The same cohort of 5 month old animals was used. 
H1rKO mice showed significantly higher food intake in the first few hours after the 
fasting period compared to WT mice. Two-way ANOVA detected a main effect of 
genotype (p<0.001) and of time (p<0.001) for the first four hours. However, the 
genotype effect was no longer present after 12 hours (Fig. 3.8). 
 
Figure 3.8: 6 hour-fasting-induced cumulative FI in WT (n=8) and H1rKO (n=8) 
1, 2, and 4 hours (A) and 12 hours (B) after refeeding. All data are expressed as 
mean ±SEM. Symbols denote significant differences between the two genotypes; 
**p<0.01, ***p<0.001 
 
3.2 Do mice lacking H1 receptors respond to anorectic doses of amylin? 
 
The aim of this experiment was to investigate whether various doses of amylin (5, 20, 
50 and 200μg/kg) reduce eating in H1rKO mice to the same extent as in WT mice.  
 
3.2.1 1-hour food intake after amylin administration 
 
Figures 3.9 and 3.10 show the cumulative FI in the first hour after amylin 
administration (5, 20 and 50μg/kg) in WT and H1rKO mice at an average age of 5 
months. Two-way ANOVA detected significant main effects of both genotype 
(p<0.05) and amylin treatment (p<0.05), and a significant difference between WT and 
KO mice observed following the 20μg/kg dose (Fig. 3.9).  
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Figure 3.9: Cumulative food intake 1 hour after saline or amylin (5, 20, 50μg/kg) 
administration in WT (n=12) and H1rKO (n=6) mice. All data are expressed as 
mean ±SEM. Symbol denotes significant difference between the two genotypes; 
*p<0.05. Two-way ANOVA detected a significant genotype effect (p<0.05) and 
an overall treatment effect (p<0.05) 
 
Plotted in a different way, Figure 3.10 illustrates the effect of amylin on food intake, 
as compared to saline, one hour after administration. The WT mice showed 
significantly reduced food intake compared to saline-treated mice (p < 0.001; Fig. 
3.10A), with significant individual differences at 20 and 50μg/kg between amylin and 
saline. This was not the case for H1rKO mice, which did not respond to any amylin 
dose tested (Fig. 3.10B). 
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Figure 3.10: Food intake after 1 hour in WT (A) and H1rKO mice (B). Symbols 
denote significant differences between the amylin-treated and the control saline 
groups; **p<0.01, ***p<0.001. One-way ANOVA detected a treatment effect in 
WT mice (p<0.001), but not in H1rKO mice 
 
While WT mice demonstrated significant decreases in food intake in the first hour 
following amylin treatment, the effect of amylin was no longer significant 2 or 4 
hours after treatment, and the effect was completely abolished 12 hours after amylin 
administration. Similar to the data from the first hour after amylin treatment, H1rKO 
mice did not show any effect of amylin on food intake at later time points (data not 
shown). 
 
Because we did not observe an amylin-induced suppression in food intake with the 
three doses tested, the feeding trials were repeated in the metabolic cages with a 
second cohort of animals, in which we also assessed the effect of an additional, higher 
dose of amylin (200μg/kg) on food intake in WT and H1rKO mice. The results for 5, 
20 and 50μg/kg amylin administration were comparable with the previous trial (data 
not shown). Unlike the H1rKO mice, the WT showed a significant reduction in 1-hour 
FI after amylin (20, 50 and 200μg/kg) compared to the WT saline control group. 
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Figure 3.11: Cumulative 1 hour food intake after saline or amylin (200μg/kg) 
administration in WT (n=4) and H1rKO (n=4) mice. All data are expressed as 
mean ±SEM 
 
With the highest dose of 200μg/kg, a main effect of amylin was observed in both WT 
and H1rKO mice (p<0.05), and no difference between genotypes was detected (Fig. 
3.11). Thus, compared to the WT mice, the H1rKO mice were generally less 
responsive to amylin administration unless the high dose of 200μg/kg was given.  
 
3.2.2 cFos activity in the area postrema 
 
Although food intake was not suppressed by amylin in H1rKO mice up to a dose of 
50μg/kg, the aim of the final experiment was to test if amylin may still induce cFos 
expression in the AP. The dose of amylin chosen to potentially induce a cFos 
response was the highest dose that had no effect on eating in the H1rKO mice at any 
time point. Thus, both WT and KO mice were injected with either saline or amylin 
(50μg/kg) at dark onset and were sacrificed 2 hours later. Due to brain sectioning 
problems, not all mice could be used for analyzing. 
 
Two-way ANOVA detected a genotype effect (p<0.05) and a treatment effect 
(p<0.001; Fig. 3.12 and 3.13). While both genotypes showed elevated cFos activity 
after amylin administration, the H1rKO mice expressed a significantly higher number 
of cFos positive cells compared to the WT mice, despite showing no anorectic 
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response after amylin. Representative photomicrographs of the AP are shown in 
Figure 3.13. 
 
 
Figure 3.12: Number of cFos positive cells in the AP of WT (n=4) and H1rKO 
(n=3) mice 2 hours after saline or amylin (50μg/kg) injection. All data are 
expressed as mean ±SEM. Symbol denotes significant differences between the 
two genotypes; **p<0.01 
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Figure 3.13: Representative photomicrographs of cFos positive cells in the area 
postrema after saline (A, C) or amylin administration (50μ/kg; B, D) in WT (A, 
B) and H1rKO (C, D) mice 
 
3.3 Do mice lacking H1 receptors respond to anorectic doses of leptin? 
 
The aim of this experiment was to investigate whether various doses of leptin 
(500μg/kg, 1, 5 and 10mg/kg) reduce eating in H1rKO mice to the same extent as in 
WT mice.  
3.3.1 Food intake after leptin administration 
 
Figure 3.14 shows cumulative food intake 1, 2 and 4 hours after dark onset, i.e. 3, 4 
and 6 hours after saline or leptin administration, in WT and H1rKO. The data show 
that none of the leptin doses significantly reduced food intake in H1rKO mice in the 
first two hours with food access, and that H1rKO mice were less responsive to higher 
doses of leptin (5 and 10mg/kg) at 4 hours after dark onset, compared to the WT 
controls. In contrast, the WT mice showed reduced food intake already in the first 
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hour of food access following the 5mg/kg dose, and responded to all doses of leptin at 
either the 2- or 4-hour time point. 
 
 
 
 
Figure 3.14: Cumulative food intake 1 hour (A, D), 2 hours (B, E) and 4 hours 
(C, F) after dark onset in WT mice (n=8; A-C) and H1rKO mice (n=8; D-F). 
Animals were injected with either saline or leptin (500μg/kg, 1, 5 or 10mg/kg) 2 
hours prior to dark onset and access to food. All data are expressed as mean 
±SEM. Symbols denote significant differences between the leptin treated and the 
control saline group; *p<0.05, **p<0.01, ***p<0.001 
 
3.3.2 pSTAT3 activity in the hypothalamus 
 
In the final experiment the aim was to test if leptin induces pSTAT3 activity in two 
nuclei of the hypothalamus (VMH and ARC), which are two main sites of leptin 
action. Mice were injected with either saline or leptin (1.3mg/kg), sacrificed 45 
minutes later, and the brains were processed to detect pSTAT3-positive neurons (Fig. 
3.15). 
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Figure 3.15: Representative photomicrographs of pSTAT3-positive cells within 
the arcuate nucleus (ARC) and the ventromedial nucleus of the hypothalamus 
(VMH) after saline (A, C) or leptin (1.3mg/kg; B, D) administration in WT (A, B) 
and H1rKO mice (C, D) 
  
Two-way ANOVA did not detect a genotype effect in either brain area, but there was 
a strong main effect of leptin in both the ARC (p<0.001) and the VMH (p<0.001). T-
test analysis showed significance in the WT animals comparing the effect of saline 
versus leptin in the ARC (p<0.001) and the VMH (p<0.01). In H1rKO mice the t-test 
showed significance only in the VMH (p<0.01) but a clear tendency in the ARC when 
comparing saline versus leptin treatment (Fig. 3.16). These data therefore 
demonstrated leptin receptor responsiveness in H1rKO mice, despite the lack of a 
leptin effect on food intake at a similar dose (1mg/kg). 
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Figure 3.16: Quantification of the number of pSTAT3-positive cells in the ARC 
(A) and the VMH (B) in WT (n=5) and H1rKO mice (n=6) 45 minutes after 
either saline or leptin (1.3mg/kg) injection. All data are expressed as mean 
±SEM. Symbols denote significant differences between treatment groups within 
the same genotype; **p<0.01, ***p<0.001 
 
3.4 Do mice lacking H1 receptors respond to a combined amylin – leptin 
administration? 
 
To investigate the interaction of amylin and leptin, a combined treatment was 
assessed using the same cohort of animals as in experiments of section 3.3 
(Experiment 4). The animals were fasted for 6 hours. Saline or leptin (1mg/kg, i.p.) 
was injected 2 hours prior to dark onset; at dark onset, saline or amylin (50μg/kg, i.p.) 
was injected just before access to food was provided. Figure 3.17 shows cumulative 
food intake 1 hour and 2 hours after dark onset in WT and H1rKO mice.  
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Figure 3.17: Cumulative food intake 1 hour (A, C) and 2 hours (B, D) after dark 
onset in WT mice (n=8; A, B) and H1rKO mice (n=8; C, D), injected with saline 
(S) or leptin (L; 1mg/kg) two hours prior to dark onset and with saline (S) or 
amylin (A; 50μg/kg) at dark onset. All data are expressed as mean ±SEM. 
Symbols denote significant differences between the treatment groups and the 
control saline-saline group; *p<0.05, **p<0.01 
 
Co-treatment of amylin and leptin in WT mice resulted in a significant decrease in 1 
and 2 hour-food intake, compared to saline treatment, (1 hour: p<0.05; Fig. 3.17A; 2 
hours: p<0.01; Fig. 3.17B). WT mice did not show reduced food intake after either 
amylin or leptin treatment alone, i.e. the outcome was different compared to the 
single-treatment experiments using the same doses of amylin and leptin (experiments 
of section 3.2 and 3.3). Unlike the WT mice, the H1rKO mice did not show decreased 
food intake after any treatment combination compared to controls (Fig. 3.17C and D). 
Notably, no responsiveness to the combined amylin-leptin treatment was detected in 
H1rKO mice.  
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4 Discussion 
 
The aim of the study was to test the hypothesis that the histaminergic system mediates 
the interaction between amylin and leptin to control food intake and body weight. 
Using mice deficient in the histamine H1 receptor, a series of experiments were 
conducted to address the role of this receptor in the control of energy homeostasis. 
The results of these experiments suggest four main findings. First, our detailed 
analysis of the metabolic phenotype of mice lacking H1r is consistent with previous 
findings in this strain of mice: the mice are obese, have elevated levels of leptin, and 
have a tendency for increased food intake during the early dark phase and for 
decreased energy expenditure. Expanding on what has been previously published 
(Morimoto et al., 1999, Mollet et al., 2001), we showed that all but very high doses of 
amylin and leptin do not suppress food intake in H1rKO mice. However, doses of 
amylin and leptin that do not alter feeding behavior were capable of inducing 
neuronal activation in key brain regions of H1rKO mice, similar to WT mice. Finally, 
our results indicate that while wild type mice show enhanced suppression of food 
intake when amylin and leptin were administered together, H1rKO mice do not. 
 
4.1 Experiment 1: Metabolic phenotyping of H1rKO mice 
 
The first aim was to better characterize the phenotype of the H1rKO mice. Previous 
studies (Morimoto et al., 1999, Mollet et al., 2001) had shown that H1rKO 
demonstrate a significantly higher growth rate and body weight compared to WT 
mice after 28 weeks of age, and exhibit higher plasma leptin and insulin levels by at 
least 48 weeks of age (Masaki et al., 2001b, Masaki et al., 2004). In our present study, 
however, it was observed that H1rKO mice had significantly higher body weight 
already by 18 weeks of age, and remained heavier for the following 6 weeks until the 
mice were sacrificed. This result is more consistent with the finding of our group by 
Mollet and colleagues that H1rKO mice already demonstrated significantly higher 
body weight by 12 weeks of age (Mollet et al., 2001).  
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In the present study, we also assessed if the levels of circulating hormones, which are 
known to reflect adiposity at least under weight stable conditions (Gloy et al., 2010), 
are altered accordingly in H1rKO mice at a time when H1rKO mice were more obese 
and when their body weight had reached 35-40g compared to 25-30g in WT mice. 
Amylin, leptin and insulin plasma levels were higher in H1rKO compared to WT 
mice, though the difference was significant only for leptin. These results are 
consistent with work from Masaki and colleagues who showed that H1rKO mice have 
elevated serum leptin levels and elevated ob mRNA expression in epididymal white 
adipose tissue (WAT) (Masaki et al., 2004). Though we did not measure glucose 
levels in our study, previous work suggests that mice deficient in H1r have a tendency 
for elevated serum glucose (Inoue et al., 1996, Masaki et al., 2004). Additionally, 
Masaki and colleagues showed that H1rKO also exhibit higher fasting serum levels of 
free fatty acids compared to WT mice at 48, but not at 12 weeks of age. Again, there 
is evidence in our study that the obesity in H1rKO might be aging related, but there is 
no clear consensus of when exactly obesity develops. 
 
We also performed the first CT analysis of body composition in H1rKO mice; this 
was done at 19 weeks of age. H1rKO mice had significantly higher fat mass in both 
intraabdominal and subcutaneous compartments, which corresponds with elevated 
body weight and leptin levels in these mice. Again, these data support previous 
studies (Masaki et al., 2004), which had shown that H1rKO mice exhibit significantly 
higher body mass by the age of 48 weeks. In this report, higher body mass was 
accompanied by higher epididymal, mesenteric, and retroperitoneal WAT mass, and 
increased triglyceride concentrations in the liver and skeletal muscle. Furthermore, 
the adipocytes in epididymal WAT were histologically larger and the amount of fat 
deposition in brown adipose tissue (BAT) was greater in H1rKO mice than in control 
mice.  
 
A factor that plays an important role in energy homeostasis is BAT and its key protein 
uncoupling protein 1 (UCP-1) (Nicholls and Locke, 1984, Boss et al., 1997, Fleury et 
al., 1997). The gene expression of the UCP family is regulated by humoral and 
neuronal factors (Gong et al., 1997, Masaki et al., 1997, Zhou et al., 1997, Hidaka et 
al., 1999, Masaki et al., 1999); e.g. leptin, administered centrally, upregulates the gene 
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expression of the UCP family (Cusin et al., 1998). Interestingly, Masaki and 
colleagues described that the expression of UCP-1 mRNA was lower in 48-week-old 
H1rKO mice compared to WT mice of the same age (Masaki et al., 2004). This might 
be related to the leptin resistance and hence lack of leptin induced upregulation of 
UCP-1 in these mice. Further, it seems plausible that the signal transduction between 
leptin and histamine neurons is involved in the central regulation of the UCP 
expression (Masaki et al., 2001b). H1 receptors are directly involved in the central 
control of energy homeostasis through sympathetic influences on UCP expression in 
BAT (Masaki et al., 2001a, b). For example, when methyl (2-[2-pyridyl]ethyl)amine 
dihydrochloride, a H1-receptor agonist, was administered for seven days into the 
lateral cerebroventricle or intraperitoneally, UCP expression in BAT was increased in 
WT but not in H1rKO mice. Thus the lack of H1 receptors, with a concomitant 
decrease of UCP expression, might contribute to the development of obesity in older 
H1rKO mice. The potential direct and causal link to leptin resistance in these mice 
remains to be tested. 
 
Previous studies had shown that H1rKO mice exhibit increased locomotor activity, 
especially during the early portion of the light phase, with decreased activity during 
the dark phase (Inoue et al., 1996). However, this study reported that total activity 
over 24 hours was not significantly different. Consistent with these results, we also 
did not detect a statistical difference between wild type and H1rKO mice when 
physical activity was measured by counting the number of beam breaks in the 
animals’ home cage over a 24-hour period. We did not measure hourly activity; 
therefore, we can only speculate that a difference between the genotypes in the early 
portion of the light phase would emerge if we were to analyze the data hour-by-hour. 
 
Moreover, the H1rKO mice showed significantly decreased ambulation and time 
spent rearing for the first 30 minutes in a new environment (Inoue et al., 1996). 
Hypothalamic histamine is released in rats forced to swim for one hour (Endou et al., 
2001), suggesting that histamine may have been released because of the stress or, 
alternatively, because the rats are performing a motivated behavior to survive. This 
could be an explanation why H1rKO show less activity in a new environment and 
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also are less prone to stress during handling, as it was seen when our mice were 
handled in the present study.  
 
We also assessed, for the first time by means of indirect calorimetry, if there were 
differences in energy expenditure between wild type and H1rKO mice during the light 
and dark phase. While not significant, we observed a tendency toward lower total 
energy expenditure in H1rKO mice. Because we saw no difference in physical 
activity, the primary cause of positive energy balance in H1rKO mice still remains to 
be determined. Measurement of core body temperature in combination with BAT 
activity (see above) and diet-induced thermogenesis will shed additional light on this 
matter. Leptin administration is a known activator of energy expenditure and 
selectively promotes fat metabolism in ob/ob mice (Hwa et al., 1997); thus decreased 
energy expenditure in H1rKO mice might directly result from decreased sensitivity to 
endogenous leptin in these mice.  
 
Finally, indirect calorimetry was also used to measure the respiratory quotient of wild 
type and H1rKO mice during both the light and dark phase in order to determine the 
primary source of energy utilized over a 24-hour period. We observed no difference 
between genotypes, suggesting that on average, both genotypes pull from similar 
energy sources (carbohydrate, fat, or protein) over the course of a day.  
 
In our study we observed that ad libitum-fed H1rKO mice have a tendency toward 
increased food intake in the first hours after dark onset, and that they also consumed 
more food during the first few hours of the dark phase following a 6-hour fast 
(p<0.001). It is possible that this is the result of decreased sensitivity to satiation 
hormones like amylin during the early dark phase; i.e. when rodents typically ingest 
their biggest meal and when the amylin effect therefore may be most pronounced. 
This notion is supported by the fact that the H1rKO mice were indeed more resistant 
to certain doses of exogenous amylin and leptin, compared to wild type controls 
(Mollet et al., 2001). Despite these observations during the early dark phase, neither 
total 24-hour cumulative food intake, nor total light or dark phase intake, were 
different across genotypes, regardless of whether mice had been fasted. This suggests 
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that differences observed during the initial dark phase are compensated for; the 
underlying mechanisms are unknown.  
Our data are consistent with previous work (Masaki et al., 2001b) showing no change 
in total 24-hour food intake; however, this pattern does appear to shift with age, as 
H1rKO mice at 48 weeks of age did consume more food than wild type mice, 
primarily during the light phase (Masaki et al., 2004). Because 24-hour food intake 
did not differ significantly between H1rKO and WT mice at this age in the present 
study, the higher body weight in H1rKO was likely due to lower energy expenditure, 
though the exact mechanism by which energy expenditure is altered remains to be 
established. Due to the known effects of amylin (Mack et al., 2007, Osaka et al., 
2008, Wielinga et al., 2010) and leptin on energy expenditure (Halaas et al., 1995, 
Halaas and Friedman, 1997, Hwa et al., 1997, Widdowson et al., 1997), it seems 
plausible that the reduced responsiveness of H1rKO to amylin and leptin may be 
involved. 
 
Previous studies have shown that a disturbed circadian feeding rhythm per se may 
result in obesity (Beck et al., 1990, Fukagawa et al., 1992, Murakami et al., 1995, 
Arble et al., 2010). For instance, studies done in obese (fa/fa) Zucker rats showed that 
the hyperphagia of these rats is characterized not only by the increased quantity of 
ingested food, but also by a redistribution of the meals during the light-dark cycle 
(Beck et al., 1992). This may be partially explained by the fact that Zucker rats have 
increased NPY concentrations within the suprachiasmatic nucleus of the 
hypothalamus, which is considered the major controller of the circadian feeding 
rhythm (Beck et al., 1992). Fukagawa and colleagues also showed that with the 
progression of age and obesity, obese Zucker rats gradually exhibit disrupted patterns 
of nocturnal feeding, drinking, and ambulation. More specifically, these obese rats eat 
larger meals during both the dark and light phase than their controls. Additionally, 
obese rats eat more frequently during the light phase, and also show increased 
ambulation during the light phase with progression of age (Fukagawa et al., 1992). 
Whether similar phenomena are present in H1rKO mice remains to be studied in 
detail. 
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To summarize, while the exact mechanism causing obesity in H1rKO mice still needs 
further elucidation, it is clear that H1rKO mice are less sensitive to the eating 
inhibitory effects of amylin and leptin. It was previously established that amylin (5 
and 20μg/kg) and leptin (1.3mg/kg) administration in H1rKO mice induces a 
markedly attenuated anorectic effect (Morimoto et al., 1999, Mollet et al., 2001). 
However, it had not been previously tested how these animals behave after the 
administration of higher doses of amylin or leptin, and whether central neuronal 
activation patterns are altered following their administration in H1rKO mice. We 
therefore investigated the feeding behavior and central neuronal response pattern in 
H1rKO mice after the administration of different doses of amylin and leptin to 
determine if the decreased amylin and leptin sensitivity in H1rKO mice is a result of 
faulty receptor functioning or a disruption in the networks downstream of the 
receptors. 
 
4.2 Experiment 2: Do mice lacking H1 receptors respond to anorectic doses of 
amylin?  
 
By assessing different doses of amylin (5, 20, 50, 200μg/kg), we observed that 
H1rKO mice are less responsive than wild type mice to all doses of amylin, except the 
highest dose (200μg/kg) tested, which caused a similar reduction in food intake in 
both genotypes. While the lack of functional H1 receptors appears to be a clear 
contributor to decreased amylin sensitivity, other factors, like dysfunctional amylin 
receptors or even obesity itself, might also lead to decreased amylin sensitivity. 
Indeed, diet-induced obese (DIO) rats show a somewhat attenuated response to 
amylin after long term exposure to a high energy diet (Boyle et al., 2011). 
 
To determine indirectly if a disruption in amylin receptor function underlies decreased 
amylin sensitivity in H1rKO mice, amylin-induced cFos activation was assessed in 
the AP of wild type and H1rKO mice. The immediate early gene product cFos acts as 
a marker of neuronal activation. Despite the differential effect on food intake, both 
WT and H1rKO mice showed significantly increased cFos activation in the AP 
following amylin treatment (50μg/kg); interestingly, H1rKO mice showed an even 
higher activity than WT mice. Our results demonstrate that the responsiveness of 
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amylin’s primary target brain area seems to be intact in H1rKO mice, and that the 
sensitivity of the AP to amylin is potentially even higher in H1rKO mice than in WT 
mice. H1rKO mice only reacted to a very high dose of amylin (200μg/kg) with a 
reduced eating response, which could have non-specific effects on receptors other 
than the CT-R. These results lead us to suggest that the lack of amylin’s effect on 
food intake in H1rKO mice most likely lies downstream of the amylin receptor in the 
AP, and that the effect observed when high doses of amylin were given potentially 
lead to the activation of additional or unspecific pathways to reduce food intake. The 
overall low number of cFos-positive cells suggests that additional optimization of the 
cFos staining protocol for mice is required. Therefore, we view this cFos study as a 
preliminary experiment that needs to be repeated. 
 
As previously discussed, the AP is functionally linked to several other brain regions, 
including the LPBE, NTS, CEA, and the BSTL (Rowland et al., 1997, Riediger et al., 
2004). Dense anatomical projections also exist from amylin activated neurons in the 
LPBE to the VMH and the ARC (Potes et al., 2010). The existence of such neuronal 
connections might explain why the AP can be still activated by amylin in H1rKO 
mice and that the reduced amylin sensitivity may exist in downstream projections. It 
seems possible, for example, that VMH-mediated signaling is diminished in H1rKO 
mice, since we know that the H1 receptors are mainly expressed within the VMH 
(Palacios et al., 1981). Thus the link between AP, LPB and VMH is probably a very 
important starting point for future studies. Furthermore, it has been proposed that 
amylin may be able to trigger histamine release which can act on hypothalamic 
histamine H1-receptors (Mollet et al., 2003). This is supported by findings that the 
monkey hypothalamus contains a discrete number of amylin-immunoreactive neurons 
which may be involved in amylin’s effect on food intake via the histaminergic system 
(D'Este et al., 2001). 
 
4.3 Experiment 3: Do mice lacking H1 receptors respond to anorectic doses of 
leptin?  
 
By assessing different doses of leptin (500μg/kg, 1, 5 and 10mg/kg), we showed here 
that H1rKO mice are less responsive to leptin treatment unless high doses (5 and 
10mg/kg) were administered. Yet, similar to what we observed with amylin-induced 
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cFos expression in the AP, leptin treatment (1.3mg/kg) induced a significant increase 
in pSTAT3 activation within the ARC and VMH of the hypothalamus in both WT and 
H1rKO mice. Again this suggests that the responsiveness of primary leptin receptors 
in the hypothalamus is still present in H1rKO mice.  
 
It is well established that chronic high-fat feeding and hyperleptinemia are associated 
with decreased pSTAT3 signaling within the hypothalamus in rats (El-Haschimi et al., 
2000, Roth et al., 2008). However, this does not seem to be the case for H1rKO mice 
despite the lack of a functional leptin response; although H1rKO mice have higher 
basal plasma leptin levels than WT mice, both genotypes mounted a similar pSTAT3 
response following leptin treatment. Due to the attenuated eating effect after low to 
moderate leptin doses, it is suggested that H1rKO mice are leptin resistant when more 
physiological concentrations of leptin are circulating within the blood. 
 
As another possible explanation of the leptin resistance in H1rKO, there is evidence 
that elevated blood leptin levels in itself may overstimulate leptin receptors, which 
leads to an upregulation of negative feedback pathways and which blocks further 
leptin signaling (Knight et al., 2010). Leptin stimulates the expression of SOCS-3, a 
protein that directly inhibits leptin signaling in the ARC (Enriori et al., 2007) and that 
acts as a negative regulator of pSTAT3 signaling in the hypothalamus. Leptin 
resistance is therefore associated with elevated SOCS-3 levels in the ARC (Munzberg 
et al., 2004). It might be possible that SOCS-3 is involved in the decrease of leptin’s 
effect on food intake in H1rKO mice in some form, but these mice are still responsive 
to higher leptin doses. High leptin doses might overcome the leptin resistance perhaps 
due to an activation of other pathways that lead to a decrease of food intake. Hence, 
studies need to be done to investigate the SOCS-3 levels in the ARC in H1rKO mice 
after different doses of leptin. 
 
Overall, we suggest that the dysfunction of leptin’s effect most likely reflects the lack 
of histamine H1 receptors, specifically in the VMH. This is supported by the fact that 
hypothalamic histamine release is increased after leptin administration (Yoshimatsu et 
al., 1999, Morimoto et al., 2000). It is likely that leptin also induces histamine release 
in H1rKO mice, but it cannot exert its effects on food intake and energy expenditure 
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because H1 receptors are absent.  
 
4.4 Experiment 4: Do mice lacking H1 receptors respond to combined amylin – 
leptin administration? 
 
As we and others have shown that H1 receptors are involved in amylin and leptin 
action (Morimoto et al., 1999, Morimoto et al., 2000, Mollet et al., 2001), the aim of 
the final part of our experiments was to investigate the effect of combined 
administration of amylin and leptin in H1rKO mice; namely whether this combination 
may also be effective in mice lacking H1 receptors.  
 
In fact, the effect of a combined treatment was only seen in WT mice. Amylin plus 
leptin treated WT mice, but not H1rKO mice, ate significantly less compared to the 
control saline-saline group. Interestingly and unexpectedly, the amount of food eaten 
was not significantly lower in WT mice treated with either amylin or leptin alone, as 
was observed in Experiments 2 and 3 where similar doses were administered. We 
speculate that this may have been due to the long stay of the mice in the metabolic 
cages. The animals were kept for more than two months under the conditions of 
individual housing in a non-diversified environment with repeated peripheral 
injections. In fact this resulted in a decreased amount of food intake in all groups 
when compared to the basic measurements of Experiment 1. However, other studies 
reported that amylin reduces food intake in rats (Lutz et al., 1994) and mice (Morley 
and Flood, 1991) after repeated peripheral or central administration and even during 
chronic administration in rats (Arnelo et al., 1996, Lutz et al., 2001). 
 
The main result regarding eating behavior in H1rKO mice was that the combined 
amylin-leptin administration did not induce a significant reduction in food intake 
compared with the saline-saline treated animals. These findings support our 
suggestion that amylin’s effect of restoring leptin responsiveness may depend on an 
intact histaminergic system; this would therefore explain why this reinforcing effect 
did not occur in mice lacking H1 receptors.  
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Although we did not test a cFos response in this experiment, we suggest that H1rKO 
mice probably have elevated cFos reactivity after amylin–leptin treatment, as it was 
the case after amylin alone in Experiment 2. We rather presume that the critical site of 
interaction is the hypothalamus. As mentioned, previous studies suggested that amylin 
interacts with leptin at the level of the VMH and the ARC; amylin pre-treatment 
increases leptin sensitivity in lean rats (Turek et al., 2010) and partially restores 
hypothalamic leptin sensitivity in leptin resistant DIO rats by reinstating normal leptin 
induced pSTAT3 activity in the VMH (Roth et al., 2008). However, future studies are 
required to test this hypothesis specifically (see section 4.5). 
 
We conclude that the histamine H1 receptor is involved in the feeding inhibitory 
effects of amylin and leptin treatment. Future studies will be necessary to prove the 
hypothesis that H1 receptors are required specifically for the amylin-leptin 
interaction. 
 
4.5 Outlook and future studies  
 
Further studies are needed to test in more detail our hypothesis that histamine plays a 
specific role in the amylin-leptin interaction. The results presented in this work only 
show that amylin and leptin are individually less active in H1rKO than WT mice. The 
lack of an eating inhibitory effect of the amylin-leptin combination treatment in 
H1rKO mice could simply be due to an abolishment of these individual effects, rather 
than of their interaction. 
 
The role of H1 receptors in this interaction will be tested based on the studies by Roth 
et al. (2008) and Turek et al. (2010). For example, future experiments will test 
whether amylin potentiates the leptin induced pSTAT3 response in the VMH in mice, 
whether amylin increases leptin receptor binding in the ARC and the VMH, and 
whether amylin increases leptin receptor mRNA expression in the hypothalamus. If 
our hypothesis were correct, all these effects would only be observed in WT, but not 
in H1rKO mice. Similar experiments will test whether leptin enhances amylin-
induced cFos expression in the AP (Roth et al., 2008) in WT but not in H1rKO mice. 
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However, it is important to note that a primary role of the AP in the amylin-leptin 
interaction seems less likely than the involvement of the VMH (Turek et al., 2010). 
 
To investigate the involvement of histamine in the VMH, it will also be worthwhile to 
investigate whether amylin, leptin or their combination trigger histamine release in 
the hypothalamus, and whether this response differs between WT and H1rKO mice. 
Finally, other brain areas, such as the PVN, which lie outside the primary ARC or 
VMH target sites, need to be investigated by assessing amylin- and leptin-induced 
neuronal markers, since there is evidence that complex neuronal connections do exist 
between these different brain areas (Palacios et al., 1981, Elmquist et al., 1998, 
Elmquist et al., 1999). 
 
Another experimental approach to test our hypothesis might be to design similar 
experiments using rats and to induce a blockade of H1 receptor in the VMH by central 
administration of H1 receptor-antagonists or virus-induced H1 receptor knockdown, 
in combination with amylin and leptin treatments. This approach would give us the 
possibility to analyze further parameters of energy expenditure (e.g. diet-induced 
thermogenesis, body temperature in multiple locations) and to very specifically target 
the H1 receptor in the VMH, without the potentially confounding developmental 
effects in the complete H1rKO mice.  
 
Finally, to overcome some technical limitations of the present studies, some 
experiments will require repeating, such as the combined amylin-leptin treatment 
experiments, to increase group size and statistical power. Also, since there were some 
technical issues with the cFos staining procedure in our mice, we decided not to count 
the cFos activated cells in the Experiment 4. This problem must be resolved for future 
studies. Various perfusion and immunohistochemical protocols from other 
laboratories should be tested. Preliminary tests examining the influence of various 
perfusion protocols on brain tissue show promising results. 
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